EUVIMEDEUVIMED entdecken
VergleichsstudieOpen Access

Risk of Hyperkalemia in Patients with Heart Failure Treated with Spironolactone in Combination with Sacubitril/Valsartan vs. Renin–Angiotensin System Inhibitors

Katherine L Crum, Muthiah Vaduganathan, Rishi J Desai iD

Clinical Pharmacology & Therapeutics · 2026-09 · 120 (3) · 806-813

DOI: 10.1002/cpt.70382 ↗

Kurz gefasst

Vergleichsstudie in der Zeitschrift Clinical Pharmacology & Therapeutics, online erschienen am 30.06.2026. Verfasst von Katherine L Crum und 2 weiteren Autor:innen. Beteiligte Einrichtung: Department of Epidemiology, Harvard T.H. Chan School of Public Health, Boston, Massachusetts, USA. Hauptthemen laut MEDLINE: Hyperkalemia, Heart Failure, Valsartan, Aminobutyrates. Die Arbeit nennt 18 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

We aimed to compare the risk of hyperkalemia in patients with heart failure initiating spironolactone while receiving sacubitril/valsartan vs. those initiating while on a RASi in a real‐world clinical setting among a heterogeneous population. We conducted a new‐user, active comparator cohort study of patients with heart failure initiating spironolactone from April 1, 2016, to July 31, 2024, using a large national commercial insurance database. Patients were classified as RASi users (continuous ACEi/ARB use ≥30 days prior to and including spironolactone initiation) or ARNI users (continuous sacubitril/valsartan use over the same period). Propensity score based fine‐stratification weighting was used for confounding control. Outcomes included hyperkalemia (serum potassium >5.5 mmol/L) and severe hyperkalemia (>6 mmol/L), assessed over a maximum follow‐up of 180 days. About 57,926 patients initiated spironolactone: 8,589 while on ARNI (mean age: 70.6 years, 39.5% female) and 49,337 while on RASi (mean age: 72.8 years, 48.6% female). Incidence rates (95% confidence intervals) for hyperkalemia were lower among ARNI users (9.44 (8.46, 10.51) vs. 12.55 (12.07, 13.04) per 100 person‐years), corresponding to a weighted rate difference of −1.20 (−1.74, −0.60) events per 100 person‐years. Adjusted hazard ratios (95% CI) were 0.89 (0.79–1.01) for hyperkalemia and 0.74 (0.57–0.95) for severe hyperkalemia. Findings were consistent across subgroups. Initiation of spironolactone among patients with heart failure receiving sacubitril/valsartan was associated with a lower risk of severe hyperkalemia, compared with RASi use. This study expands upon previous findings suggesting the risk of hyperkalemia when using MRAs may be mitigated through the substitution of sacubitril/valsartan for RASi.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

HyperkalemiaHeart FailureValsartanAminobutyratesBiphenyl CompoundsSpironolactoneAngiotensin-Converting Enzyme InhibitorsAngiotensin Receptor AntagonistsTetrazolesHumansFemaleMaleDrug CombinationsAgedMiddle AgedRenin-Angiotensin SystemDrug Therapy, CombinationMineralocorticoid Receptor AntagonistsRisk FactorsAged, 80 and over

Substanzen

Drug CombinationsValsartanAminobutyratesBiphenyl CompoundsSpironolactonesacubitril and valsartan sodium hydrate drug combinationAngiotensin-Converting Enzyme InhibitorsAngiotensin Receptor AntagonistsTetrazolesMineralocorticoid Receptor Antagonists

Autor:innen und Institutionen

  • Department of Epidemiology, Harvard T.H. Chan School of Public Health, Boston, Massachusetts, USA.
  • Division of Pharmacoepidemiology and Pharmacoeconomics, Department of Medicine, Brigham and Women's Hospital and Harvard Medical School, Boston, Massachusetts, USA.
  • Division of Cardiovascular Medicine, Brigham and Women's Hospital, Boston, Massachusetts, USA.

ORCID-Profile: Rishi J Desai

Zitieren

APA

Crum, K. L., Vaduganathan, M., & Desai, R. J. (2026). Risk of Hyperkalemia in Patients with Heart Failure Treated with Spironolactone in Combination with Sacubitril/Valsartan vs. Renin–Angiotensin System Inhibitors. Clinical Pharmacology & Therapeutics, 120(3), 806-813. https://doi.org/10.1002/cpt.70382

Vancouver

Crum KL, Vaduganathan M, Desai RJ. Risk of Hyperkalemia in Patients with Heart Failure Treated with Spironolactone in Combination with Sacubitril/Valsartan vs. Renin–Angiotensin System Inhibitors. Clinical Pharmacology & Therapeutics. 2026;120(3):806-813. doi:10.1002/cpt.70382

BibTeX
@article{Crum2026,
  author = {Crum, Katherine L and Vaduganathan, Muthiah and Desai, Rishi J},
  title = {Risk of Hyperkalemia in Patients with Heart Failure Treated with Spironolactone in Combination with Sacubitril/Valsartan vs. Renin–Angiotensin System Inhibitors},
  journal = {Clinical Pharmacology & Therapeutics},
  year = {2026},
  volume = {120},
  number = {3},
  pages = {806--813},
  doi = {10.1002/cpt.70382}
}
Kostenlos starten →